(Q33416851)

26 July 2017

title

Immunogenicity and other problems associated with the use of biopharmaceuticals (English)

1 reference

26 July 2017

2

Christophe Lallemand

1 reference

26 July 2017

Michael G Tovey

1

0 references

publication date

1 June 2011

1 reference

Therapeutic advances in drug safety

26 July 2017

published in

1 reference

26 July 2017

volume

2

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

113-128

1 reference

A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Progressive multifocal leukoencephalopathy and newer biological agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interleukin 2 in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

The role of natalizumab in the treatment of multiple sclerosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Erythropoietin in cancer patients: pros and cons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Demyelination as a complication of new immunomodulatory treatments

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Sensing and signaling in antiviral innate immunity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Rituximab: mechanism of action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

One-step assay for quantification of neutralizing antibodies to biopharmaceuticals

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Alemtuzumab and multiple sclerosis: therapeutic application

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Mechanisms of induction and action of interferons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Natalizumab for the treatment of relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Type I IFNs and their role in the development of autoimmune diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

The risk of infections with biologic therapies for rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Association of an IRF5 gene functional polymorphism with Sjögren's syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Drug-induced lupus due to anti-tumor necrosis factor alpha agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Immunogenicity of protein therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Measurement of cytokines by bioassays: theory and application

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

The type I interferon system in systemic lupus erythematosus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Side effects of interferon-alpha therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interferon and the central nervous system

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Etanercept plus standard therapy for Wegener's granulomatosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Thyroid autoimmunity and dysfunction associated with type I interferon therapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Immunogenicity of biological therapeutics: a hierarchy of concerns.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Thrombocytopenia caused by the development of antibodies to thrombopoietin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Pegylation: a novel process for modifying pharmacokinetics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Dermatomyositis after interferon alpha treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Mood and cognitive side effects of interferon-alpha therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Immunogenicity and allergenic potential of animal and human insulins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Mechanisms of fever induced by recombinant human interferon

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110816

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Daclizumab to prevent rejection after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

STAT4is a genetic risk factor for systemic sclerosis having additive effects withIRF5on disease susceptibility and related pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

The CGGGG insertion/deletion polymorphism of theIRF5promoter is a strong risk factor for primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611406318

Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists

21 January 2018

1 reference

12 December 2020

Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series

1 reference

12 December 2020

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1 reference

12 December 2020

Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population

1 reference

12 December 2020

Role of aggregated human growth hormone (hGH) in development of antibodies to hGH

1 reference

12 December 2020

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy?

1 reference

12 December 2020

Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta

1 reference

12 December 2020

The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis

1 reference

12 December 2020

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

12 December 2020

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report

1 reference

12 December 2020

Diagnosis of melanoma under concomitant natalizumab therapy

1 reference

12 December 2020

New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson

1 reference

12 December 2020

Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C

1 reference

12 December 2020

Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families

1 reference

12 December 2020

PML problems loom for Rituxan

1 reference

12 December 2020

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

12 December 2020

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1177/2042098611406318

1 reference

26 July 2017

1 reference

26 July 2017

1 reference